EUVIMEDEUVIMED entdecken
EditorialKommentar

Reply: Spatial and temporal manipulation of the Scn1a gene affect adult brain function

Claudia Di Berardino, Martina Mainardi, Simone Brusco, Elena Benvenuto, Vania Broccoli, Gaia Colasante iD

Brain · 2024

DOI: 10.1093/brain/awad423 ↗

Kurz gefasst

Editorial in der Zeitschrift Brain, 2024. Verfasst von Claudia Di Berardino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Nervous System Physiological Phenomena. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We appreciated Dr Jansen and colleagues’ (from now on ‘the authors’) interest1 in our recently published work in Brain.2 In this study, we investigated the effects of global delayed induction of Scn1a gene haploinsufficiency at two distinct postnatal time points (P30 and P60) in mice, comparing them to perinatally (P2) induced haploinsufficiency. At the beginning of their letter, the authors reported a sentence of our abstract and stated that they disagree on the novelty claim of that sentence, referring to previous publications to support their statement.3-5 We acknowledge their disappointment, and we value their initiative in writing a Letter to the Editor to articulate the reasons for their divergence. On our side, we are pleased to have the opportunity to respond and further express our point of view on their observations. At the origin of their divergence there is their idea that the effects of delayed ablation/reduction of Nav1.1 expression on epilepsy phenotype have been already reported in those studies,3-5 and that the only difference with our work is methodology. We agree on the fact that methodologies are different between our study and the previously cited works3-5 and the reason is that we all posed very different questions and hence set the best model to answer them. Therefore, in our opinion the main difference is not ‘only methodology’ but, most importantly, the question we posed and that makes our work novel in the field. The first two works3,4 address similar questions related to the specific role of distinct brain areas underlying Dravet syndrome characteristic phenotypes. In particular, Stein et al.3 investigated ‘the specific loci of Nav1.1 function in the brain that underlie Dravet global deficits’ while Jansen and colleagues4 focused on ‘the role of different brain regions in epilepsy networks in Dravet syndrome’. To answer those specific questions, they performed full ablation (and not heterozygous inactivation that is what happens in Dravet condition) of Scn1a gene expression by local delivery in the hippocampus3,4 or cerebral cortex4 of an adeno-associated viral (AAV) vector expressing the Cre recombinase in a Scn1aflox/flox model. In both cases viral injections for Cre delivery were performed at P21, likely because it was the earliest time point at which stereotactic surgery could be easily done and not because the effect of delayed local gene ablation was sought. In agreement with that, the concept of temporal relevance of Scn1a gene expression has never been expressed and/or discussed throughout the two manuscripts. We were well aware of these two publications and also of others based on selective downregulation of Scn1a gene in specific brain areas of adult rats6-8 and we consider them extremely relevant for the field. We have used these works as a foundation for conducting other experiments that aim to dissect which brain areas need to be prioritized in a potential locally delivered treatment for Dravet syndrome. We are using our Scn1aStop/+ reversible mouse model9 of Dravet syndrome for these investigations and we will be happy to discuss our results in the context of those published works in our next manuscript. In the third work reported by the authors, the effect of interneuron dysfunction on brain networks was studied in the attempt to define biomarkers for epileptogenesis.5 Again, a very different question from our own. Here, the authors uncovered a decrease in theta-gamma coupling associated with seizure activity in Dravet syndrome mice. To assess if this is directly linked to interneurons defect or it is a secondary consequence of interneuron dysfunction on cortical network maturation during the critical period, they made a single experiment to induce Scn1a gene haploinsufficiency in adult mice (P42–P56) but still locally, in the hippocampus. We acknowledge that this experiment provides the first inference that localized Scn1a haploinsufficiency in adult mice can induce seizures. Nevertheless, the authors did not explicitly discuss it in their manuscript leaving the utility of that experiment confined to their specific research question. Of note, only epilepsy was assessed in this study, while other symptoms characteristic of Dravet syndrome were not investigated. Conversely, in our work we induced global Scn1a gene haploinsufficiency at two different time points (P30 and P60) across postnatal mouse development and assessed the effect on the whole spectrum of Dravet syndrome phenotype. Indeed, our specific aim was to answer the question of the advantage of preserving physiological levels of Nav1.1 during the critical time window of brain development in the context of treatment delivery and its specific timing, as the same authors evidenced. This is also the aspect that we prioritized in the discussion of the manuscript, given the scope of the work and our specific background. However, differently from what they perceived, we were not alluding to the usage of locally delivered therapies, but to globally delivered treatments, like antisense oligonucleotides acting on Scn1a expression or gene therapies based on artificial transcription factors to boost gene expression, coupled with systemic delivery strategies once that AAV variants efficiently crossing human blood–brain barrier will be available. This is the ultimate reason why we exploited a genetic model in which we induced global gene haploinsufficiency. Based on this evidence, we believe that the novelty of our work cannot be questioned and the Reviewers, who are clearly experts in the field, shared the same view. That said, we appreciated and are grateful to the authors for the interesting insights and discussion points they provided in their letter, which we fully share. We have only one additional comment to make on the discrepancy in the effect on cognitive deficits between what we observed upon the global delayed induction of Scn1a gene haploinsufficiency and the results obtained when Scn1a was completely ablated only in the hippocampus.3 The difference in the two experiments is not only in the gene expression level (heterozygous versus full knock-out) and spatial extent of inactivation (global versus local), but in the timing as well. In fact, while in Dr Catterall lab’s work Scn1a was deleted at P21, still within the critical period of brain development, in our work we propose that assuring normal expression of Nav1.1 in the brain for longer time, up to P30 and P60, may contribute to the ameliorative effect on cognitive performance observed in comparison to perinatal Scn1a haploinsufficiency induction in mice. As the authors report, other previous works showed that local knockdown (KD) of Nav1.1 in the medial septum6,7 or in the hippocampus8 of adult rats can induce cognitive impairment without seizures and this may seem contradictory to our observations. However, the deficit observed, assessed by reaction-to-novelty task, is specific for a reaction to spatial changes and associated with an impairment of theta oscillations in the hippocampus. Interestingly, when rats were tested in Morris water maze—the same test we performed—escape latency did not differ between Nav1.1 KD and control groups, suggesting an intact spatial reference memory.7 This might indicate a minor sensitivity of the Morris water maze assay in detecting specific alterations of theta oscillations-related circuit functions. Nevertheless, this test—widely used in the characterization of the Dravet syndrome phenotype9,10—highlighted spatial reference deficits in P2-induced mice. These deficits were ameliorated in P30-induced mice and rescued in P60-induced Dravet mice. Alternatively, this discrepancy in cognitive performance might also depend on species-specific effects (rats versus mice) and/or on the use of a local KD model. While, on one side, it allows dissecting the contribution of a brain circuit to a specific behaviour, on the other side, it overlooks the impact of circuit-circuit interaction in the generation of complex behaviours. Finally, given that those local KD model did not display seizures, these studies ultimately support that cognitive impairment in Dravet syndrome is independent from epilepsy and thus that cognitive amelioration we observed in delayed induced mice cannot be reconducted to the inferior time experienced in seizures by P30- and P60-induced mice. In conclusion, we thank the authors for providing an opportunity to discuss some of our data in the context of previous reports and to highlight the novelty of our study with respect to those works. We believe that this novelty resides in the global delayed induction of Scn1a gene haploinsufficiency to mimic the proper genetic condition of Dravet syndrome that allowed us to investigate the impact of the maintenance of physiological Nav1.1 levels in the critical phase of brain development. Data sharing is not applicable to this article as no new data were created or analysed in this study. No funding was received towards this work. The authors report no competing interests.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsy, Temporal LobeNervous System Physiological PhenomenaAdultHumansNAV1.1 Voltage-Gated Sodium ChannelBrain

Substanzen

NAV1.1 Voltage-Gated Sodium Channel

Autor:innen und Institutionen

  • Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Neuroscience and Experimental Neurology PhD Program, Vita-Salute San Raffaele University, 20132 Milan, Italy.
  • Institute of Neuroscience, National Research Council (CNR), 20129 Milan, Italy.
  • Gene and Cell Therapy PhD Program, Vita-Salute San Raffaele University, 20132 Milan, Italy.

ORCID-Profile: Gaia Colasante

Zitieren

APA

Di Berardino, C., Mainardi, M., Brusco, S., Benvenuto, E., Broccoli, V., & Colasante, G. (2024). Reply: Spatial and temporal manipulation of the Scn1a gene affect adult brain function. Brain. https://doi.org/10.1093/brain/awad423

Vancouver

Di Berardino C, Mainardi M, Brusco S, Benvenuto E, Broccoli V, Colasante G. Reply: Spatial and temporal manipulation of the Scn1a gene affect adult brain function. Brain. 2024. doi:10.1093/brain/awad423

BibTeX
@article{DiBerardino2024,
  author = {Di Berardino, Claudia and Mainardi, Martina and Brusco, Simone and Benvenuto, Elena and Broccoli, Vania and Colasante, Gaia},
  title = {Reply: Spatial and temporal manipulation of the Scn1a gene affect adult brain function},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awad423}
}
Kostenlos starten →